Tasipimidine Formulations And Use Thereof

Orion Corporation
Application Awaiting Examination App No 202317069526 Chemical

Patent information

IP India · live record
Application number
202317069526
Filing date
16 October 2023
Status
Application Awaiting Examination
Publication number
36/2024
Publication type
INA
Invention field
Chemical

Abstract

The present disclosure relates to a pharmaceutical composition in the form of an orally deliverable liquid composition comprising tasipimidine, or a pharmaceutically acceptable salt thereof, as an active ingredient and to the use thereof in the treatment and prevention of a disorder, condition or disease where an alpha2A agonist is indicated to be useful, for example, for use as a sedative or analgesic agent, and for use in the treatment of anxiety or agitation. The composition is stable at the pH range from about 2.0 to about 5.0.

Applicants

1
Finland
ORION CORPORATION Orionintie 1 02200 Espoo

Inventors

4
Finland
KUJALA, Johannac/o ORION CORPORATION P.O.Box 65 02101 Espoo
Finland
LEHTISALO, Jennic/o ORION CORPORATION P.O.Box 65 02101 Espoo
Finland
SALMIA, Jukkac/o ORION CORPORATION P.O.Box 65 02101 Espoo
Finland
SINERVO, Kaic/o ORION CORPORATION P.O.Box 65 02101 Espoo

Documents

Sign in to open
Application documents
1 202317069526-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [16-10-2023(online)].pdf 16 Oct 2023
2 202317069526-STATEMENT OF UNDERTAKING (FORM 3) [16-10-2023(online)].pdf 16 Oct 2023
3 202317069526-FORM 1 [16-10-2023(online)].pdf 16 Oct 2023
4 202317069526-DECLARATION OF INVENTORSHIP (FORM 5) [16-10-2023(online)].pdf 16 Oct 2023
5 202317069526-COMPLETE SPECIFICATION [16-10-2023(online)].pdf 16 Oct 2023
6 202317069526-FORM-26 [27-12-2023(online)].pdf 27 Dec 2023
7 202317069526-Proof of Right [18-03-2024(online)].pdf 18 Mar 2024
8 202317069526-FORM 3 [18-03-2024(online)].pdf 18 Mar 2024
9 202317069526-FORM 18 [24-12-2024(online)].pdf 24 Dec 2024